Response,Percentage of R&D investments
Pre-human/pre-clinical,16.4%
Clinical trials,49.2%
Phase I*,9.7%
Phase II*,10.6%
Phase III*,28.9%
Approval,3.3%
Pharmacovigiliance (Phase IV),11.6%
Uncategorized,19.4%
